# A Drug-Drug Interaction Study to Estimate the Effect of PF-07081532 on the Pharmacokinetics of Dabigatran and Rosuvastatin in Overweight or Obese Adult Participants

> **NCT05788328** · PHASE1 · TERMINATED · sponsor: **Pfizer** · enrollment: 16 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Dabigatran etexilate (DE)
- **DRUG:** Rosuvastatin
- **DRUG:** PF-07081532

## Key facts

- **NCT ID:** NCT05788328
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2023-03-27
- **Primary completion:** 2023-09-11
- **Final completion:** 2023-09-11
- **Target enrollment:** 16 (ACTUAL)
- **Why stopped:** The decision to terminate clinical development of lotiglipron is based on pharmacokinetic data from Phase 1 drug-drug-interaction studies and laboratory measurements of elevated transaminases in these Phase 1 studies as well as a Phase 2 study.
- **Last updated:** 2024-11-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05788328

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05788328, "A Drug-Drug Interaction Study to Estimate the Effect of PF-07081532 on the Pharmacokinetics of Dabigatran and Rosuvastatin in Overweight or Obese Adult Participants". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05788328. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*